US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

45.71

-0.1400-0.31%

Volume:32.13K

Turnover:1.47M

Market Cap:13.98B

PE:20.50

High:45.72

Open:45.61

Low:45.37

Close:45.85

52wk High:55.49

52wk Low:45.37

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.66

T/O Rate:0.01%

Dividend:2.06

Dividend Rate:4.50%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.54

PE(LYR):18.54

Loading ...

Overview Company News Filings

Emera Gets Final Approval for Sale of New Mexico Gas to Bernhard Capital Partners

MT Newswires Live

Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

IBM (NYSE: IBM) Stock Recovery: Bouncing From $201 Toward 50 EMA After Q2 Reset

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid

Simply Wall St.

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Roche announces EMA’s CHMP recommended approval of Susvimo

Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55

MT Newswires Live

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Emera (EMA) Gets a Hold from Desjardins

Analysts Offer Insights on Utilities Companies: Emera (EMA) and Brookfield Renewable (BEPC)

J.P. Morgan Sticks to Its Hold Rating for Emera (EMA)

Emera price target raised to C$77 from C$74 at CIBC

GSK announces EMA accepted submission to update Bexsero label

BMO Capital Sticks to Its Buy Rating for Emera (EMA)

CIBC Keeps Their Hold Rating on Emera (EMA)

Emera price target raised to C$77 from C$74 at CIBC

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/EMA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.71,"timestamp":1791553379201,"preClose":45.85,"halted":0,"volume":32126,"delay":0,"changeRate":-0.003053435114503829,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Trading","change":-0.14,"latestTime":"10-09 09:43:30 EDT","open":45.61,"high":45.72,"low":45.37,"amount":1465115.4180359999,"amplitude":0.007634,"askPrice":45.75,"askSize":500,"bidPrice":45.67,"bidSize":600,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":45.85,"dividendRate":0.045038,"postHourTrading":{"tag":"盘后","latestPrice":45.85,"preClose":45.85,"latestTime":"19:30 EDT","volume":1119037,"amount":51326168.544014,"timestamp":1791502204763,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.662251,"impliedVol":0.2321,"impliedVolPercentile":0.6454},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.662251,"shares":305783111,"dividePrice":2.0587,"high":45.72,"amplitude":0.007634,"preClose":45.85,"low":45.37,"week52Low":45.37,"pbRate":"1.54","psRate":"2.23","week52High":55.49,"institutionHeld":0,"latestPrice":45.71,"committee":0.090909,"eps":2.229761,"divideRate":0.045038,"volume":32126,"delay":0,"ttmEps":2.229761,"open":45.61,"prevYearClose":49.24,"prevWeekClose":48.03,"prevMonthClose":47.83,"prevQuarterClose":47.83,"fiveDayClose":48.03,"twentyDayClose":49.19,"sixtyDayClose":54.64,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"date":"2026-11-06","symbol":"EMA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/09","expectedEps":0.69,"defaultRemindTime":1793955600000,"name":null,"time":"Pre-MKt","dateTimestamp":1793941200000,"actualEps":null},{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-10-08","current":20.499955,"percent":0.223529,"low":16.637027,"twenty":18.01228,"median":20.214257,"eighty":20.998463,"high":22.07626,"avg":19.838598,"sd":1.438583,"marketCap":14099837784.32},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36},{"date":"2026-09-25","current":19.941415,"twenty":17.94243,"median":20.238018,"eighty":21.011747,"marketCap":14658867103.01},{"date":"2026-10-02","current":20.032985,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"marketCap":14620461610.8},{"date":"2026-10-08","current":19.306338,"twenty":18.01228,"median":20.214257,"eighty":20.998463,"marketCap":14099837784.32}],"updateTime":1791553410438},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655889133","title":"Emera Gets Final Approval for Sale of New Mexico Gas to Bernhard Capital Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2655889133","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655889133?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:18","pubTimestamp":1785439123,"startTime":"0","endTime":"0","summary":"Emera  received final approval from the New Mexico Public Regulation Commission for the sale of New Mexico Gas to Bernhard Capital Partners in a $1.25 billion deal.The deal is expected to close in August, Emera said Thursday in a statement.Proceeds of $650 to $700 million will be used to support investment opportunities across Emera's regulated utility businesses and help repay debt, according to the statement.Price: 54.16, Change: +0.14, Percent Change: +0.26","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","BK4081","BK7129","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872868","title":"Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872868?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"greatest potential for success. The strategy concentrates resources on. blarcamesine across three CNS indications: early Alzheimer's disease and. Rett syndrome, where the Company's clinical and regulatory foundation is. most advanced, and Fragile X, where FDA Orphan Drug Designation,supportive preclinical and biomarker data, and the absence of any. approved therapy may lead to a promising regulatory path with the FDA.Alzheimer's Disease Program-- At the end of March 2026, the Company opened an Investigational New Drug.  application for early Alzheimer's disease with the FDA. This is an. important milestone: the IND enables clinical studies to be conducted in. the U.S. and provides the basis for substantive discussions with the FDA. to align on the Company's future clinical development for early. -- Two foundational clinical pharmacology studies are proceeding","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","CHMP","BK4081","ADME","BK4110","LU1878469433.USD","CNS","BK4022","BK4087","BK4585","BK4139","SOCL","BK4232","BK4097","R","RPD","BK4588","BK4085","DDI","BK4135","EMA","AAIC","LABU","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892689","title":"IBM (NYSE: IBM) Stock Recovery: Bouncing From $201 Toward 50 EMA After Q2 Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892689","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892689?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:00","pubTimestamp":1785337200,"startTime":"0","endTime":"0","summary":"IBM bounced 5.6% Monday from its $201.60 post-earnings low and is approaching the $233 50 EMA resistance. Q2 confirmed software +5%, mainframe -42%, and guidance of 4-5% growth. The securities investigation remains active. RSI at 65 approaching overbought.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20231220/728a2406d1097bb0c7c294d232e1967c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20231220/728a2406d1097bb0c7c294d232e1967c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262061416-ibm-stock-recovery-forecast-july-29-2026-post-earnings-50-ema-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBM","BK4134","EMA","SKYY","BK4538","BK4602","LU0868494617.USD","BK4575","XQTM","BK4612","BK4081","QPUX","LU1894683348.USD","BK4534","WQTM","BK4588","LU1894683264.USD","LU1880398471.USD","BK4585","LU1880398554.USD","BK4579","BK4533","LU1674673691.USD","NYSE","LU0321505868.SGD","LU1585245621.USD","BK4543","LU1883839398.USD","LU0321505439.SGD","LU1778281490.HKD","LU1430594728.SGD","TDIV","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655896416","title":"The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655896416","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655896416?lang=en_us&edition=fundamental","pubTime":"2026-07-29 22:05","pubTimestamp":1785333900,"startTime":"0","endTime":"0","summary":"--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Pri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335380/0/en/The-Lancet-Publishes-HOPE-3-Data-for-Capricor-Therapeutics-Deramiocel-in-Duchenne-Muscular-Dystrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOPE","ATMP","CAPR","BK4211","EMA","BK4139","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001704","title":"Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001704?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:50","pubTimestamp":1785239443,"startTime":"0","endTime":"0","summary":"Lantern Pharma (LTRN) announced that an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 in advanced, recurrent b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","BK4139","BK4081","GDOC","LTRN","NVIB","IDNA","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098656","title":"Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098656","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098656?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:24","pubTimestamp":1785111889,"startTime":"0","endTime":"0","summary":"In July 2026, Zevra Therapeutics reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol in Niemann-Pick disease type C, prompting the company to seek a formal re-examination while maintaining patient access through its global Expanded Access Program.\nThe updated international Consensus Clinical Management Guidelines for Niemann-Pick disease type C highlight arimoclomol...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-zvra-is-down-254-after-ema-rejects-arimoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAA","ZVRA","BK4588","BK4007","BK4215","BK4585","BK4081","SPRE","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654206030","title":"Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654206030","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654206030?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  26, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/26/3333236/0/en/Ascentage-Pharma-Chairman-and-CEO-Dr-Dajun-Yang-Named-to-The-Medicine-Maker-Power-List-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4234","BK4081","AAPG","BK4139","EMA","BK4084","PW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653847087","title":"Roche announces EMA’s CHMP recommended approval of Susvimo","url":"https://stock-news.laohu8.com/highlight/detail?id=2653847087","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653847087?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:50","pubTimestamp":1784897430,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-emas-chmp-recommended-approval-of-susvimo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","HRTS","03165","EPV","BK4007","BK4087","EMA","CHMP","BK4081","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785088","title":"Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785088?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:28","pubTimestamp":1784885304,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted a marketing authorization application to the European Medicines Agency and European Commission for CT-P55, a biosimilar to Cosentyx , according to a bourse filing on Friday.The company seeks approval for adult plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis, plus pediatric plaque psoriasis and juvenile idiopathic arthritis subtypes.The application is based on a Phase 1 trial in 172 healthy subjects that demonstrated pharmacokinetic equivalence to Cosentyx, with similar safety profiles and low immunogenicity across both groups.The company cautions that submitting an application does not guarantee final approval, and regulatory reviews may yield unexpected outcomes or lead to changes in commercialization plans.This MAA follows prior EMA submissions and approvals for the drug's clinical trial applications between 2023 and 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","EMA","BK4081","IND","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653556757","title":"BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1","url":"https://stock-news.laohu8.com/highlight/detail?id=2653556757","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653556757?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:30","pubTimestamp":1784719800,"startTime":"0","endTime":"0","summary":"- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331254/0/en/BridgeBio-Announces-FDA-Acceptance-of-NDA-for-Encaleret-for-ADH1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4183","BK4585","SPRE","PTH","BK4081","MAA","BK4215","BK4588","ENDO","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653675789","title":"Emera (EMA) Gets a Hold from Desjardins","url":"https://stock-news.laohu8.com/highlight/detail?id=2653675789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653675789?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:19","pubTimestamp":1784672383,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brent Stadler from Desjardins maintained a Hold rating on Emera, with a price target of C$74.00. The company’s shar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-desjardins-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-desjardins-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778988","title":"Analysts Offer Insights on Utilities Companies: Emera (EMA) and Brookfield Renewable (BEPC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653778988?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:10","pubTimestamp":1784671851,"startTime":"0","endTime":"0","summary":"Companies in the Utilities sector have received a lot of coverage today as analysts weigh in on Emera (EMA) and Brookfield Renewable (BEPC). Emera ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-brookfield-renewable-bepc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-brookfield-renewable-bepc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","IE00BMG7P702.HKD","IE00BMG7P926.USD","BK4081","IE00BMG7P694.USD","BEPC","BK4133","IE00BMG7P587.USD","IE00BMG7P819.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653378552","title":"J.P. Morgan Sticks to Its Hold Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653378552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653378552?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:47","pubTimestamp":1784666833,"startTime":"0","endTime":"0","summary":"In a report released today, Eli Jossen from J.P. Morgan maintained a Hold rating on Emera, with a price target of C$79.00. According to TipRanks, J...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653210199","title":"Emera price target raised to C$77 from C$74 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2653210199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653210199?lang=en_us&edition=fundamental","pubTime":"2026-07-21 01:20","pubTimestamp":1784568030,"startTime":"0","endTime":"0","summary":"CIBC raised the firm’s price target on Emera (EMA) to C$77 from C$74 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297452","title":"GSK announces EMA accepted submission to update Bexsero label","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297452","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297452?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:40","pubTimestamp":1784544023,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced the European Medicines Agency, EMA, has accepted a submission to update the label for Bexsero to include a single dose booster ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-ema-accepted-submission-to-update-bexsero-label-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-ema-accepted-submission-to-update-bexsero-label-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","GSK.UK","EMA","GSK","EPV","BK4081","BK4532","GSKH","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652252371","title":"BMO Capital Sticks to Its Buy Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652252371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652252371?lang=en_us&edition=fundamental","pubTime":"2026-07-19 23:55","pubTimestamp":1784476520,"startTime":"0","endTime":"0","summary":"In a report released on July 17, Benjamin Pham from BMO Capital reiterated a Buy rating on Emera, with a price target of C$76.00. The company’s sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-emera-ema-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMO","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652394282","title":"CIBC Keeps Their Hold Rating on Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652394282","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652394282?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:55","pubTimestamp":1784307317,"startTime":"0","endTime":"0","summary":"In a report released today, Mark Jarvi from CIBC maintained a Hold rating on Emera, with a price target of C$77.00. Jarvi covers the Utilities sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cibc-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cibc-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284238","title":"Emera price target raised to C$77 from C$74 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652284238?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:10","pubTimestamp":1784304633,"startTime":"0","endTime":"0","summary":"CIBC analyst Mark Jarvi raised the firm’s price target on Emera (EMA) to C$77 from C$74 and keeps a Neutral rating on the shares. In a sector previ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c77-from-c74-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652422420","title":"Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2652422420","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652422420?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:35","pubTimestamp":1784234123,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals (VNDA) announced that the Committee for Orphan Medicinal Products at the European Medicines Agency has adopted a positive opi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vanda-announces-ema-positive-opinion-for-orphan-drug-designation-of-imsidolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vanda-announces-ema-positive-opinion-for-orphan-drug-designation-of-imsidolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA","VNDA","BK4139","EPV","BBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}